TY - JOUR
T1 - Advances and controversies in management of breast ductal carcinoma in situ (DCIS)
AU - Farante, Gabriel
AU - Toesca, Antonio
AU - Magnoni, Francesca
AU - Lissidini, Germana
AU - Vila, José
AU - Mastropasqua, Mauro
AU - Viale, Giuseppe
AU - Penco, Silvia
AU - Cassano, Enrico
AU - Lazzeroni, Matteo
AU - Bonanni, Bernardo
AU - Leonardi, Maria Cristina
AU - Ripoll-Orts, Francisco
AU - Curigliano, Giuseppe
AU - Orecchia, Roberto
AU - Galimberti, Viviana
AU - Veronesi, Paolo
N1 - Funding Information:
The authors would like to thank Eva Bruschini and Maria Grazia Villardita for the preparation of the manuscript and William Russell-Edu for the MEDLINE research and Editing. This work was partially supported by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds. Jose Vila was supported by a grant from the Umberto Veronesi Foundation .
Publisher Copyright:
© 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology
PY - 2022/4
Y1 - 2022/4
N2 - Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. It accounts for 25% of all breast cancers diagnosed, as a result of the expansion of breast cancer screening and is associated with a high survival rate. DCIS is particularly clinically challenging, due to its heterogeneous pathological and biological traits and its management is continually evolving towards more personalized and less aggressive therapies. This article suggests evidence-based guidelines for proper DCIS clinical management, which should be discussed within a multidisciplinary team in order to propose the most suitable approach in clinical practice, taking into account recent scientific studies. Here we include updated multidisciplinary treatment protocols and techniques in accordance with the most recent contributions published on this topic in the peer-reviewed medical literature, and we outline future perspectives.
AB - Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. It accounts for 25% of all breast cancers diagnosed, as a result of the expansion of breast cancer screening and is associated with a high survival rate. DCIS is particularly clinically challenging, due to its heterogeneous pathological and biological traits and its management is continually evolving towards more personalized and less aggressive therapies. This article suggests evidence-based guidelines for proper DCIS clinical management, which should be discussed within a multidisciplinary team in order to propose the most suitable approach in clinical practice, taking into account recent scientific studies. Here we include updated multidisciplinary treatment protocols and techniques in accordance with the most recent contributions published on this topic in the peer-reviewed medical literature, and we outline future perspectives.
KW - Breast cancer
KW - Ductal carcinoma in situ
KW - Guidelines
KW - Medical treatment
KW - Radiotherapy
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85118841225&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118841225&partnerID=8YFLogxK
U2 - 10.1016/j.ejso.2021.10.030
DO - 10.1016/j.ejso.2021.10.030
M3 - Review article
C2 - 34772587
AN - SCOPUS:85118841225
SN - 0748-7983
VL - 48
SP - 736
EP - 741
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
IS - 4
ER -